Enter your email address
Submit
Write your message
Volume 17, Issue 4 (Iranian Journal of Breast Diseases 2025)
ijbd 2025, 17(4): 32-51 |
Back to browse issues page
Ethics code: IR.SBMU.RETECHREC.1401.129
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
haghighat S, Omidi Z, Farajivafa V, Ansari M, Bagheri A, Sajadian A, et al . Exploratory and confirmatory factor analysis of the Persian Version of the European Organization for Research and Treatment of Cancer Quality of Life- Breast Cancer questionnaires with 45 and 42 items: EORTC QLQ-BR45 and QLQ-BR42. ijbd 2025; 17 (4) :32-51
URL: http://ijbd.ir/article-1-1155-en.html
URL: http://ijbd.ir/article-1-1155-en.html
Shahpar Haghighat1 
, Zahra Omidi1 , Vahid Farajivafa1 , Maryam Ansari1 , Aida Bagheri2 , Akram Sajadian1 , Shiva Moghadam1 , Hossein Foudazi3 , Farid Zayeri *4
, Zahra Omidi1 , Vahid Farajivafa1 , Maryam Ansari1 , Aida Bagheri2 , Akram Sajadian1 , Shiva Moghadam1 , Hossein Foudazi3 , Farid Zayeri *4
1- Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
2- Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
3- Fayazbakhsh Hospital, Social Security Organization, Tehran, Iran
4- Proteomics Research Center and Department of Biostatistics, Faculty of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran ,fzayeri@gmail.com
2- Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
3- Fayazbakhsh Hospital, Social Security Organization, Tehran, Iran
4- Proteomics Research Center and Department of Biostatistics, Faculty of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran ,
Abstract: (665 Views)
Introduction: The EORTC QLQ-BR45 and QLQ-BR42 questionnaires have been developed to measure the quality of life in breast cancer patients, with 22 and 19 additional items, respectively, compared to the QLQ-BR23 questionnaire. The current project had the objective of evaluating the construct validity of the Persian translation of the QLQ-BR45 and QLQ-BR42 questionnaires.
Methods: After confirming the Persian translation of the EORT QLQ-BR45 questionnaire, 480 samples were enrolled in the study for its psychometric evaluation. Confirmatory factor analysis was used to assess the performance of the item and scale of the QLQ-BR45 and QLQ-BR42 questionnaires' total scores and their subscales. Due to the lack of statistical acceptance of the calculated indices, the construct validity of the 23 and 22 questions of QLQ-BR45 was assessed separately to suggest a more appropriate scoring system for these questionnaires.
Results: In the confirmatory factor analysis of the EORTC QLQ-BR45 tool, the indices RMSEA, NFI, NNFI, and CFI were 0.099, 0.516, 0.638, and 0.676, respectively. The QLQ-BR42 factor analysis showed that the indices were 0.111, 0.742, 0.6, and 0.646, respectively. The factor analysis results for the QLQ-BR23 tool showed NFI, NNFI, CFI, and RMSEA values of 0.830, 0.886, 0.909, and 0.061, respectively. In 22 additional items of the QLQ-BR45, these indexes were 0.853, 0.917, 0.913, and 0.07, respectively, all of which indicate acceptable model fit.
Conclusion: As per the current study, the 45 items in the EORTC QLQ-BR45 tool are not a good fit in the combined factor model. Instead of integrating the two sections mentioned, it is suggested that the new 22-item tool be used as an instrument to assess the quality of life in breast cancer patients.
Methods: After confirming the Persian translation of the EORT QLQ-BR45 questionnaire, 480 samples were enrolled in the study for its psychometric evaluation. Confirmatory factor analysis was used to assess the performance of the item and scale of the QLQ-BR45 and QLQ-BR42 questionnaires' total scores and their subscales. Due to the lack of statistical acceptance of the calculated indices, the construct validity of the 23 and 22 questions of QLQ-BR45 was assessed separately to suggest a more appropriate scoring system for these questionnaires.
Results: In the confirmatory factor analysis of the EORTC QLQ-BR45 tool, the indices RMSEA, NFI, NNFI, and CFI were 0.099, 0.516, 0.638, and 0.676, respectively. The QLQ-BR42 factor analysis showed that the indices were 0.111, 0.742, 0.6, and 0.646, respectively. The factor analysis results for the QLQ-BR23 tool showed NFI, NNFI, CFI, and RMSEA values of 0.830, 0.886, 0.909, and 0.061, respectively. In 22 additional items of the QLQ-BR45, these indexes were 0.853, 0.917, 0.913, and 0.07, respectively, all of which indicate acceptable model fit.
Conclusion: As per the current study, the 45 items in the EORTC QLQ-BR45 tool are not a good fit in the combined factor model. Instead of integrating the two sections mentioned, it is suggested that the new 22-item tool be used as an instrument to assess the quality of life in breast cancer patients.
Type of Study: Research |
Subject:
Epidemiology
Received: 2024/11/7 | Accepted: 2024/12/18 | Published: 2024/12/27
Received: 2024/11/7 | Accepted: 2024/12/18 | Published: 2024/12/27
References
1. Ferlay J, Laversanne M, Ervik M, Lam F, Colombet M, Mery L, et al. Global cancer observatory: Cancer Tomorrow. (2020). Available at: https://gco.iarc.fr/tomorrow/en
2. Haghighat Sh, Omidi Z, Ghanbari-Motlagh A. Trend of breast cancer incidence in Iran during a fifteen-year interval according to national cancer registry reports. Iranian Journal of Breast Diseases, 2022;15(2):4-17. [DOI:10.30699/ijbd.15.2.4]
3. Mahdavifar N, Pakzad R, Ghoncheh M, Pakzad I, Moudi A, Salehiniya H. Spatial Analysis of Breast Cancer Incidence in Iran. Asian Pac J Cancer Prev. 2016;17(S3):59-64. doi: 10.7314/apjcp.2016.17.s3.59. PMID: 27165209. [DOI:10.7314/APJCP.2016.17.S3.59] [PMID]
4. Javan Biparva A, Raoofi S, Rafiei S, Pashazadeh Kan F, Kazerooni M, Bagheribayati F, et al. Global quality of life in breast cancer: systematic review and meta-analysis. BMJ Support Palliat Care. 2024 Jan 8;13(e3):e528-e536. doi: 10.1136/bmjspcare-2022-003642. [DOI:10.1136/bmjspcare-2022-003642] [PMID] []
5. Sprangers M, Groenvold M, Arraras J I, Franklin J, Velde A te, Muller M. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. Journal of clinical oncology, 1996. 14(10):2756-68. [DOI:10.1200/JCO.1996.14.10.2756] [PMID]
6. Marta GN, Moraes FY, Leite ETT, Chow E, Cella D, Bottomley A. A critical evaluation of quality of life in clinical trials of breast cancer patients treated with radiation therapy. Ann Palliat Med. 2017;6(Suppl 2):S223-S232. doi: 10.21037/apm.2017.09.06. [DOI:10.21037/apm.2017.09.06] [PMID]
7. Nguyen J, Popovic M, Chow E, Cella D, Beaumont JL, Chu D, et al. EORTC QLQ-BR23 and FACT-B for the assessment of quality of life in patients with breast cancer: a literature review. J Comp Eff Res. 2015;4(2):157-66. doi: 10.2217/cer.14.76. [DOI:10.2217/cer.14.76] [PMID]
8. Montazeri A, Harirchi I, Vahdani M, Khaleghi F, Jarvandi S, Ebrahimi M, et al. The EORTC breast cancer-specific quality of life questionnaire (EORTC QLQ-BR23): translation and validation study of the Iranian version. Qual Life Res. 2000;9(2):177-84. doi: 10.1023/a:1008918310251. [DOI:10.1023/A:1008918310251] [PMID]
9. Bjelic-Radisic V, Cardoso F, Cameron D, Brain E, Kuljanic K, da Costa RA, et al. EORTC Quality of Life Group and Breast Cancer Group. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. Ann Oncol. 2020 Feb;31(2):283-8. doi: 10.1016/j.annonc.2019.10.027. [DOI:10.1016/j.annonc.2019.10.027] [PMID]
10. Bjelic-Radisic V, Cardoso F, Weis J, Velikova G, Cameron D.A, Brain, E.G.C et al. 270MO An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: Results of the validation study phase IV EORTC QLQ-BR42. ESMO Open. ESMO Breast Cancer 2024, 15-17 May 2024, Berlin, Germany. Elsevier [DOI:10.1016/j.esmoop.2024.103329]
11. Bouya S, Koochakzai M, Rafiemanesh H, Balouchi A, Taheri S, Badakhsh M, et al. Health-related quality of life of Iranian breast cancer patients: a meta-analysis and systematic review. Breast Cancer Res Treat. 2018;170(2):205-12. doi:10.1007/s10549-018-4750-x. [DOI:10.1007/s10549-018-4750-x] [PMID]
12. Lemieux J, Goodwin PJ, Bordeleau LJ, Lauzier S, Théberge V. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009). J Natl Cancer Inst. 2011;103(3):178-231. doi: 10.1093/jnci/djq508. [DOI:10.1093/jnci/djq508] [PMID]
13. Wheelwright S, Bjordal K, Bottomley A, Gilbert A, Martinelli F, Pe M, et al. EORTC Quality of Life Group Guidelines for Developing Questionnaire Modules. 2021; Available from: https://www.eortc.org/app/ uploads/sites/2/2022/07/Module-Guidelines-Version-5-FINAL.pdf.
14. Haghighat Sh, Zayeri F, Montazeri A, Ebrahimi M. Factor validity of Persian version of the lymphedema life impact scale (LLIS)
15. questionnaire in breast cancer induced lymphedema. Iranian Journal of Breast Diseases, 2017;10(2):27-37.
16. Getu MA, Wang P, Kantelhardt EJ, Seife E, Chen C, Addissie A. Translation and validation of the EORTC QLQ-BR45 among Ethiopian breast cancer patients. Sci Rep. 2022;12(1):605. doi: 10.1038/s41598-021-02511-9. [DOI:10.1038/s41598-021-02511-9] [PMID] []
17. Tan ML, Idris DB, Teo LW, Loh SY, Seow GC, Chia YY, Tin AS. Validation of EORTC QLQ-C30 and QLQ-BR23 questionnaires in the measurement of quality of life of breast cancer patients in Singapore. Asia Pac J Oncol Nurs. 2014;1(1):22-32. doi: 10.4103/2347-5625.135817. [DOI:10.4103/2347-5625.135817] [PMID] []
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
